Semaglutide Salt Forms Explained: Base vs. Sodium vs. Acetate — What the FDA Says

Why Does “Salt Form” Matter?

In pharmaceutical chemistry, the same drug molecule can exist in different chemical forms. The “base” form is the pure active molecule. A “salt” form attaches a counter-ion — like sodium or acetate — to the peptide. This isn’t just a labeling technicality. The presence of a salt counter-ion changes the molecule’s physicochemical properties, potentially affecting solubility, stability, how it absorbs in the body, and how long it remains active.

Think of it this way: table salt (sodium chloride) and potassium chloride taste similar but have very different effects in your body, especially on your heart. The same principle applies here — chemically related doesn’t mean clinically identical.

The Three Forms of Semaglutide

Semaglutide Base

This is the active pharmaceutical ingredient (API) in every FDA-approved semaglutide product. The STEP clinical trial program (which produced the headline 15% weight loss results) used semaglutide base. The SUSTAIN trials for diabetes used semaglutide base. Every safety and efficacy data point you’ve read about semaglutide comes from studies on the base form.

When a compounding pharmacy uses semaglutide base, the active molecule in your vial is chemically identical to what Novo Nordisk puts in Wegovy pens. The differences are in manufacturing quality control, not the molecule itself.

Semaglutide Sodium

Semaglutide sodium attaches a sodium ion to the peptide. This changes the molecular weight, potentially alters how the drug dissolves in solution, and may affect absorption after injection. The FDA has received adverse event reports specifically linked to semaglutide sodium products. Because this form was never part of any approved drug application, it has not undergone the extensive human safety and toxicology testing required for approval.

Semaglutide Acetate

Semaglutide acetate uses an acetate counter-ion instead of sodium. The same fundamental concern applies: changed physicochemical properties, no clinical trial data, and FDA adverse event reports associated with this form. Some compounders have used acetate because the API was cheaper or more readily available from overseas suppliers.

Why Compounders Use Salt Forms

Understanding the “why” helps patients evaluate risk. There are two primary reasons compounders have turned to salt forms:

Patent restrictions: Novo Nordisk holds patents on semaglutide base. Some compounders argued that using a chemically distinct salt form avoided patent infringement. This legal theory has not been validated in court, and the FDA’s position is clear that salt forms are not acceptable for compounding under the FD&C Act.

Supply and cost: Semaglutide sodium and acetate have historically been cheaper and more available from API suppliers, particularly overseas manufacturers. When demand for compounded semaglutide exploded during the shortage era (2022–2024), some compounders turned to salt forms simply because they could source them faster.

What the FDA Actually Says

The FDA’s position is unambiguous. In enforcement communications and warning letters throughout 2024 and 2025, the agency has stated that semaglutide salt forms are “different active ingredients” from the approved base. The agency has explicitly said it is “not aware of any lawful basis for their use in compounding.”

Warning letters issued to compounders like GLP-1 Solution and JulyMD cited the use of salt forms as grounds for charges of marketing “unapproved new drugs” and “misbranding.” As of mid-2025, the FDA’s adverse event reporting system (FAERS) had logged over 605 reports associated with compounded semaglutide — and the agency specifically flagged salt forms as a contributing factor in some of those reports.

Practical Risks for Patients

The salt form distinction isn’t abstract chemistry. It has practical implications:

Dosing uncertainty: If the pharmacokinetics of a salt form differ from the base, then the dose-response relationship changes. A dose that produces optimal weight loss with semaglutide base might produce a stronger or weaker effect with a sodium or acetate salt — and the direction of that difference hasn’t been systematically studied.

Side effect profile: The adverse event reports associated with salt forms may reflect true pharmacological differences. Some patients report different intensity of gastrointestinal side effects when switching between products that may use different forms.

Stability: Salt forms may have different stability profiles in solution. A multi-dose vial that maintains potency for 28 days with the base form might degrade faster (or slower) with a salt form. Without stability testing specific to the salt, beyond-use dates on the vial may not be reliable.

How to Protect Yourself

If you’re using or considering compounded semaglutide, here’s how to determine what’s in your vial:

1. Ask directly: Contact your provider or pharmacy and ask: “Do you use semaglutide base or a salt form (sodium or acetate)?” A reputable pharmacy will answer immediately and transparently. The correct answer is “base only.”

2. Request the Certificate of Analysis (COA): This document from the API supplier will identify the exact form of semaglutide used. Look for “semaglutide” (base) vs. “semaglutide sodium” or “semaglutide acetate.”

3. Check the label: Your vial label should identify the active ingredient. If it says “semaglutide sodium” or “semaglutide acetate,” you now know it’s a salt form.

4. Verify API sourcing: Ask whether the active ingredient comes from an FDA-registered facility. Pharmaceutical-grade semaglutide base from FDA-registered suppliers is available, but it costs more than salt forms from unregistered overseas sources.

The Bigger Picture: Why This Matters for the Industry

The salt form controversy illustrates a broader challenge in the compounding industry. During the semaglutide shortage (2022–2024), demand massively outpaced the supply of pharmaceutical-grade base API. Some compounders prioritized meeting demand over sourcing the correct form, and patients were largely unaware of the distinction.

As of 2026, enforcement has narrowed the landscape significantly. The FDA’s February 2026 enforcement announcement, 30+ warning letters in March 2026, and Novo Nordisk’s 132 federal lawsuits have put intense pressure on providers to use only semaglutide base if they compound at all. The compounders that remain in operation and are using base form API from registered suppliers represent the most legitimate segment of the market.

For patients, the practical takeaway is simple: verify what’s in your vial. A five-minute conversation with your pharmacy can confirm you’re receiving the form of semaglutide that has actual clinical data behind it.